J Clin Pharmacol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (18)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fuse, E.
Right arrow Articles by Figg, W. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fuse, E.
Right arrow Articles by Figg, W. D.

REVIEW

Review of UCN-01 Development: A Lesson in the Importance of Clinical Pharmacology

Eiichi Fuse, PhD, Takashi Kuwabara, PhD, Alex Sparreboom, PhD, Edward A. Sausville, MD, PhD and William D. Figg, PharmD

From the Clinical Pharmacology Research Core, National Cancer Institute, Bethesda, Maryland (Dr Fuse, Dr Sparreboom, Dr Sausville, Dr Figg), and Pharmacokinetic Research Laboratories, Pharmaceutical Research Institute, Kyowa Hakko Kogyo Co, Shizuoka, Japan (Dr Fuse, Dr Kuwabara).

UCN-01 is a protein kinase inhibitor under development as a novel anticancer drug. The initial pharmacologic features in patients were not predicted from preclinical experiments. The distribution volume and the systemic clearance were much lower than those in experimental animals (mice, rats, and dogs), and the elimination half-life was unusually long (>200 hours). The unbound fraction in human plasma was also much smaller than that in dogs, rats and mice, as was the binding of UCN-01 to human alpha-1 acid glycoprotein much stronger than that to human serum albumin or human {gamma}-globulin. The association constants for alpha-1 acid glycoprotein and human plasma were approximately 8 x 108(mol/L)-1, indicating extremely high affinity. In this review article, the authors discuss the pharmacologic features of UCN-01 across species and provide a perspective on how this information could be applied prospectively to the future development of this agent.

Key Words: UCN-01 • drug development • anticancer drug • pharmacology

Address for reprints: William D. Figg, PharmD, Clinical Pharmacology Research Core, National Cancer Institute, 9000 Rockville Pike, Bethesda, MD 20892.




This article has been cited by other articles:


Home page
 Molecular Cancer TherapeuticsHome page
H. Hamed, W. Hawkins, C. Mitchell, D. Gilfor, G. Zhang, X.-Y. Pei, Y. Dai, M. P. Hagan, J. D. Roberts, A. Yacoub, et al.
Transient exposure of carcinoma cells to RAS/MEK inhibitors and UCN-01 causes cell death in vitro and in vivo
Mol. Cancer Ther., March 1, 2008; 7(3): 616 - 629.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
Y. Dai, P. Khanna, S. Chen, X.-Y. Pei, P. Dent, and S. Grant
Statins synergistically potentiate 7-hydroxystaurosporine (UCN-01) lethality in human leukemia and myeloma cells by disrupting Ras farnesylation and activation
Blood, May 15, 2007; 109(10): 4415 - 4423.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by the American College of Clinical Pharmacology